Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that
Ruhi Khan has been named Vice President, Business Development, reporting
to President and CEO Ron Cohen, M.D.
Previously, Ms. Khan was the Executive Director, Business Development at
Acorda. Before joining the Company, Ms. Khan was the Senior Director of
Business Development at Lexicon Pharmaceuticals. While at Lexicon, she
led the business development function for both in-licensing and
out-licensing of programs, research stage collaborations, technology
assessments, spin-outs and other strategic initiatives. She was also
responsible for market research and market analysis for clinical product
candidates. Prior to that, Ms. Khan was a Director at Fidelity
Biosciences, the biotech venture capital investment division at Fidelity
Investments; in that capacity, she had operational management
responsibilities at EnVivo Pharmaceuticals, a biotech company focused on
the development of therapies for central nervous system disorders. Ms.
Khan has a Bachelor of Arts from Harvard College and a Master of
Business Administration from the Wharton School.
“I’m delighted to announce the promotion of Ruhi Khan to Vice President
of Business Development,” Dr. Cohen said. “Ruhi’s first assignment after
joining Acorda was to lead our process to obtain a commercialization
partner for Fampridine-SR outside the U.S. She did an outstanding job of
executing this process and concluding a great deal with an optimal
partner, Biogen Idec. I expect Ruhi to continue to be a major
contributor to Acorda’s future successes as we work to capitalize on
business development opportunities and build shareholder value.”
About Acorda Therapeutics
Acorda Therapeutics is a biotechnology company developing therapies for
spinal cord injury, multiple sclerosis and related nervous system
disorders. The Company's marketed products include Zanaflex Capsules®
(tizanidine hydrochloride), a short-acting drug for the management of
spasticity. The Company's pipeline includes a number of products in
development for the treatment, regeneration and repair of the spinal
cord and brain.
Forward-Looking Statements
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects should be
considered forward-looking.
